Revinty Ellipta (Fluticasone Furoate/Vilanterol)
Once-daily ICS/LABA combination inhaler for asthma and COPD
Quick facts about Revinty Ellipta
Key takeaways about Revinty Ellipta
- Once-daily dosing: A single inhalation each day, taken at approximately the same time, provides 24-hour asthma and COPD control through the combined action of fluticasone furoate (ICS) and vilanterol (LABA)
- Not a rescue inhaler: Revinty Ellipta is a preventer medicine for regular daily use and must not be used to relieve acute asthma attacks or sudden breathlessness – always keep a short-acting bronchodilator available
- Breath-actuated Ellipta device: The pre-loaded 30-dose dry powder inhaler requires no priming or shaking, and its ergonomic design simplifies correct use for patients who struggle with metered-dose inhalers
- LABA safety requirement: Vilanterol is a long-acting beta-agonist and should only be used in combination with the inhaled corticosteroid component; LABA monotherapy in asthma is associated with increased risk of severe exacerbations
- Rinse after each dose: Rinsing the mouth with water (and spitting it out) after each inhalation significantly reduces the risk of oral candidiasis and hoarseness, two common local side effects
What Is Revinty Ellipta and What Is It Used For?
Revinty Ellipta is a once-daily combination inhaler that delivers fluticasone furoate 92 mcg (an inhaled corticosteroid) and vilanterol 22 mcg (a long-acting beta-2 agonist) in a single breath. It is indicated for the regular maintenance treatment of asthma in patients aged 12 years and older who are not adequately controlled on an inhaled corticosteroid alone, and for symptomatic treatment of adults with moderate-to-severe COPD.
Revinty Ellipta contains two complementary active substances in a single pre-metered dose. Fluticasone furoate is a highly potent inhaled corticosteroid that reduces inflammation within the airways by binding to intracellular glucocorticoid receptors and down-regulating the expression of pro-inflammatory genes. Vilanterol (as vilanterol trifenatate) is a selective long-acting beta-2 adrenergic agonist that activates beta-2 receptors on bronchial smooth muscle, producing sustained bronchodilation that lasts approximately 24 hours following a single dose.
The medicine is delivered via the Ellipta inhaler, a breath-actuated dry powder inhaler (DPI) that contains two blister strips, each with 30 pre-metered doses. When you slide the cover open, one dose from each strip is simultaneously exposed and mixed for inhalation. This design eliminates the need for hand-breath coordination, shaking, or priming that conventional pressurised metered-dose inhalers (pMDIs) require. The device also includes a dose counter that decreases from 30 to 0 with each use, giving a clear indication of remaining doses.
In asthma, Revinty Ellipta is used as a step-up maintenance therapy when adequate control cannot be achieved with an inhaled corticosteroid alone and a short-acting beta-agonist “as-needed” reliever. According to the Global Initiative for Asthma (GINA) 2024 report, fixed-dose ICS/LABA combinations represent a standard treatment option at steps 3 and 4 of the asthma treatment ladder, particularly in patients who experience persistent daytime or night-time symptoms, reduced exercise tolerance, or frequent use of rescue bronchodilators despite ICS therapy.
In chronic obstructive pulmonary disease (COPD), the same strength (92/22 mcg) is indicated for the symptomatic treatment of adults with a forced expiratory volume in 1 second (FEV1) less than 70% of predicted normal (post-bronchodilator) who have a history of exacerbations despite regular bronchodilator therapy. Clinical trials including the landmark SUMMIT study have demonstrated that fluticasone furoate/vilanterol reduces the annual rate of moderate and severe COPD exacerbations, improves lung function, and improves health-related quality of life in this patient population.
It is important to understand that Revinty Ellipta is a preventer (controller) medicine, not a reliever. Its benefits build up over days and weeks of consistent daily use. Patients should continue taking their prescribed dose every day, even when they feel well or asymptomatic, in order to maintain stable airway inflammation control and prevent exacerbations. A separate short-acting bronchodilator (such as salbutamol or albuterol) must always be available for the relief of acute symptoms.
Revinty Ellipta is a long-term maintenance medicine and does not act fast enough to relieve an acute asthma attack or episode of sudden wheezing. During an acute episode, use your prescribed quick-relief (rescue) bronchodilator inhaler. If your rescue inhaler does not provide adequate or lasting relief, seek urgent medical attention immediately.
What Should You Know Before Taking Revinty Ellipta?
Before starting Revinty Ellipta, tell your doctor about all medical conditions – especially heart disease, high blood pressure, diabetes, hyperthyroidism, tuberculosis, or any active lung infection – and every medicine you take. Certain antifungal, antiviral, and beta-blocker medications may interact with Revinty Ellipta. Special precautions apply during transition from oral corticosteroids.
Contraindications
Do not use Revinty Ellipta if you are allergic (hypersensitive) to fluticasone furoate, vilanterol trifenatate, or any of the other ingredients of this medicine (principally lactose monohydrate and magnesium stearate). The lactose excipient contains small amounts of milk proteins; patients with severe cow’s milk protein allergy should inform their prescriber, as extremely rare hypersensitivity reactions have been reported.
Hypersensitivity reactions, though rare, can include rash, urticaria (hives), pruritus (itching), and in very rare cases angioedema – swelling of the lips, tongue, face, or throat – or anaphylaxis. Any suspected severe allergic reaction after using Revinty Ellipta is a medical emergency requiring immediate discontinuation and urgent medical care.
Warnings and Precautions
Speak with your doctor before using Revinty Ellipta if you have, or have had, any of the following conditions. Several require careful monitoring or may mean that an alternative treatment is more suitable.
- Heart or circulation problems – including coronary artery disease, arrhythmias, heart failure, or recent heart attack. Vilanterol can cause a small increase in heart rate and may worsen pre-existing cardiovascular conditions
- High blood pressure – vilanterol may cause a transient rise in blood pressure; careful monitoring is advised
- Hyperthyroidism – beta-agonists can exacerbate symptoms of an overactive thyroid
- Diabetes mellitus – inhaled beta-agonists may cause small increases in blood glucose, and corticosteroids can contribute to glucose dysregulation
- Pulmonary tuberculosis, or any active fungal, viral, or bacterial respiratory infection – inhaled corticosteroids may mask or worsen infection. Treatment for infection should be considered before starting Revinty Ellipta
- Low blood potassium (hypokalaemia) – high doses of beta-agonists can lower serum potassium, increasing arrhythmia risk, particularly when combined with diuretics or digoxin
- Severe liver disease – hepatic impairment reduces clearance of both fluticasone furoate and vilanterol, increasing systemic exposure and the risk of systemic corticosteroid effects
During treatment with Revinty Ellipta, contact your doctor promptly if you notice any of the following warning signs that your respiratory disease is deteriorating or that treatment is not working as expected:
- Worsening breathlessness, wheezing, chest tightness, or coughing
- Increasing use of your short-acting rescue inhaler (more than 2–3 times per week for asthma)
- Waking at night due to asthma symptoms
- Reduced peak expiratory flow readings (if you use a peak flow meter)
- Paradoxical bronchospasm – wheezing or difficulty breathing that develops immediately after inhalation. This is a potentially serious reaction and requires discontinuation of the medicine
- Vision changes, including blurred vision, eye pain, or seeing halos around lights – these may indicate cataracts or glaucoma
Long-acting beta-agonists (LABA) such as vilanterol should not be used to treat asthma without concomitant inhaled corticosteroid therapy. LABA monotherapy has been associated with an increased risk of asthma-related serious adverse events, including hospitalisation and death. In Revinty Ellipta, vilanterol is always combined with fluticasone furoate, which addresses this safety concern. Do not use additional LABA-containing inhalers at the same time.
If you are currently taking systemic corticosteroid tablets (for example prednisolone) for asthma or COPD, Revinty Ellipta may be introduced as your doctor tapers the oral dose. This transition must be supervised carefully because long-term oral corticosteroid use can suppress adrenal function, and abrupt withdrawal may lead to adrenal insufficiency.
Signs of adrenal insufficiency include fatigue, weakness, loss of appetite, weight loss, nausea, vomiting, low blood pressure, and darkening of skin creases. During physiological stress (serious illness, injury, or surgery) your doctor may temporarily prescribe supplementary oral corticosteroids. Patients who have received long-term oral steroids should carry a steroid warning card.
Pregnancy and Breastfeeding
There is limited clinical data on the use of fluticasone furoate/vilanterol during human pregnancy. Animal studies have not shown direct harmful effects at therapeutic exposures, but higher doses have produced adverse effects typical of potent beta-agonists and corticosteroids. Revinty Ellipta should only be used during pregnancy if the expected benefit to the mother justifies any potential risk to the fetus.
The GINA 2024 and NICE guidelines emphasise that poorly controlled asthma during pregnancy carries greater maternal and fetal risk than the use of inhaled medicines. Uncontrolled asthma is associated with preterm birth, low birth weight, pre-eclampsia, and higher perinatal mortality. The general principle is to maintain good asthma control throughout pregnancy using the lowest effective doses of conventional controller medicines.
It is not known whether fluticasone furoate or vilanterol pass into human breast milk, although animal data suggest low concentrations are present. A decision on whether to continue or discontinue breastfeeding – or to continue or discontinue Revinty Ellipta – should weigh the benefit to the infant of breastfeeding and the benefit to the mother of treatment. Women should consult their doctor in each individual case.
Children Under 12 Years
Revinty Ellipta is not recommended for children under the age of 12 years. The safety and efficacy of fluticasone furoate/vilanterol in younger children have not been established, and paediatric asthma is generally managed with inhaled corticosteroid monotherapy or combinations licensed for younger age groups.
Use in Elderly Patients
No specific dose adjustment is required for patients aged 65 years and older. However, older patients are more likely to have concomitant cardiovascular disease, diabetes, or osteoporosis, and should be monitored for the typical systemic effects of inhaled corticosteroids and beta-agonists. Patients with COPD often fall into this age group.
Driving and Operating Machinery
Revinty Ellipta is unlikely to have any clinically relevant effect on the ability to drive or operate machinery. You can continue normal daily activities while using this medicine.
How Does Revinty Ellipta Interact with Other Drugs?
The most clinically significant interactions are with strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, ritonavir, and clarithromycin), which increase systemic exposure to both active components. Non-selective beta-blockers can oppose the bronchodilator action of vilanterol and should generally be avoided.
Both fluticasone furoate and vilanterol undergo extensive hepatic metabolism primarily via the cytochrome P450 3A4 (CYP3A4) enzyme system. Medicines that strongly inhibit CYP3A4 can slow the clearance of both active ingredients, leading to markedly increased plasma concentrations and a higher risk of systemic corticosteroid effects (such as adrenal suppression) and cardiovascular effects (such as tachycardia or palpitations).
Tell your doctor or pharmacist about every medicine you are taking, have recently taken, or might take. This includes prescription medicines, over-the-counter products, herbal remedies, and dietary supplements. Combining Revinty Ellipta with any long-acting beta-agonist, high-dose short-acting beta-agonist, or other inhaled corticosteroid should always be discussed with your prescriber.
Major Interactions
| Interacting Drug / Class | Example Medicines | Effect | Clinical Recommendation |
|---|---|---|---|
| Strong CYP3A4 inhibitors | Ketoconazole, itraconazole, ritonavir, cobicistat, clarithromycin, telithromycin | Markedly increased systemic exposure to both fluticasone furoate and vilanterol; increased risk of corticosteroid and cardiovascular side effects | Concurrent use is not recommended unless the benefit outweighs the risk of systemic side effects. Monitor for adrenal suppression, tachycardia, and QT changes |
| Non-selective beta-blockers | Propranolol, sotalol, timolol (including eye drops) | Reduce or block the bronchodilator effect of vilanterol; may precipitate severe bronchospasm in asthma | Avoid unless there is a compelling indication. If a beta-blocker is needed, use a cardio-selective beta-1 agent with close respiratory monitoring |
| Cardio-selective beta-blockers | Atenolol, bisoprolol, metoprolol | May attenuate vilanterol response, particularly at higher beta-blocker doses | Use with caution and monitor pulmonary function. Generally preferred over non-selective beta-blockers if a beta-blocker is clinically required |
| Potassium-lowering drugs | Loop or thiazide diuretics, digoxin, theophylline, systemic corticosteroids | Additive hypokalaemia with beta-agonist therapy; increased arrhythmia risk | Monitor serum potassium, especially in severe asthma exacerbations or in patients with cardiovascular comorbidity |
| Other LABA-containing inhalers | Salmeterol, formoterol, olodaterol, indacaterol | Duplication of therapy; increased risk of cardiovascular and metabolic side effects without additional benefit | Do not use two LABA-containing products simultaneously. Review all inhaler prescriptions at every visit |
Minor Interactions and Considerations
Moderate CYP3A4 inhibitors – such as erythromycin, diltiazem, verapamil, and fluconazole – can produce smaller, dose-dependent increases in exposure to fluticasone furoate and vilanterol. The clinical significance is generally lower than with strong inhibitors, but dose reduction or closer monitoring may be appropriate in vulnerable patients.
Tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs), and medicines known to prolong the QT interval should be used with caution in combination with Revinty Ellipta because beta-agonists can potentiate their cardiovascular effects. Caffeine-containing drinks and sympathomimetic decongestants may also slightly increase the likelihood of tremor, palpitations, and nervousness.
Revinty Ellipta is not affected by food or drink. Alcohol does not directly interact with the medicine, but heavy alcohol use is generally discouraged in patients with asthma or COPD. Grapefruit juice, a known CYP3A4 inhibitor, is unlikely to cause clinically relevant changes in exposure at typical dietary intakes but should be discussed with your doctor if consumed regularly in large quantities.
Each dose of Revinty Ellipta contains lactose monohydrate as a carrier powder. The amount is small (approximately 25 mg per dose) and generally does not cause symptoms in patients with lactose intolerance. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. Because the lactose is derived from cow’s milk, patients with severe milk-protein allergy should seek medical advice before use.
What Is the Correct Dosage of Revinty Ellipta?
The recommended dose of Revinty Ellipta 92/22 mcg is one inhalation once daily, at the same time each day. Do not take more than one inhalation per day. The higher strength (184/22 mcg) is only for asthma, not COPD. Dosage does not require adjustment for age, kidney impairment, or mild-to-moderate liver disease.
Always use Revinty Ellipta exactly as your doctor has prescribed. Do not change the dose or stop treatment without consulting your doctor, even if your symptoms have improved. The therapeutic aim is to achieve and maintain good disease control on the lowest effective step of combination therapy. For asthma, this is part of the GINA stepwise approach; for COPD, GOLD guidelines emphasise symptom and exacerbation control.
Adults and Adolescents (12 Years and Older) with Asthma
Standard Dose for Asthma
One inhalation of Revinty Ellipta 92/22 mcg, once daily, at the same time each day (morning or evening). Most patients begin to notice improvement in lung function and symptoms within 15 minutes of the first dose due to vilanterol’s onset of bronchodilation, with full steady-state anti-inflammatory effect developing over 1–2 weeks.
Higher Strength for Severe Asthma (Adults Only)
One inhalation of Revinty Ellipta 184/22 mcg, once daily. The higher fluticasone furoate strength may be appropriate for adults whose asthma remains uncontrolled on the 92/22 mcg dose. This strength is authorised only for asthma in adults (18 years and older) and is not indicated for adolescents or for COPD.
Adults with COPD
Standard Dose for COPD
One inhalation of Revinty Ellipta 92/22 mcg, once daily. This is the only strength indicated for COPD. The higher strength (184/22 mcg) has not demonstrated additional benefit in COPD and is not authorised for this indication.
| Patient Group | Indication | Strength | Dose & Frequency |
|---|---|---|---|
| Adolescents & adults (≥12 yrs) | Asthma (standard) | 92/22 mcg | 1 inhalation once daily |
| Adults (≥18 yrs) | Asthma (severe/uncontrolled) | 184/22 mcg | 1 inhalation once daily |
| Adults (≥18 yrs) | COPD | 92/22 mcg | 1 inhalation once daily |
| Children <12 years | Asthma | Not recommended | Use an age-appropriate alternative |
| Elderly (≥65 yrs) | Asthma or COPD | No dose adjustment | As per indication above |
| Renal impairment | Asthma or COPD | No dose adjustment | As per indication above |
| Moderate-to-severe hepatic impairment | Asthma or COPD | Maximum 92/22 mcg | Use with caution; monitor for systemic effects |
How to Use the Revinty Ellipta Inhaler
It is essential that your doctor, nurse, or pharmacist demonstrates correct inhaler technique before you start treatment. The Ellipta device is designed to be straightforward, but a few key steps are critical to ensure the medicine reaches your lungs. The inhaler is ready to use from the box – no shaking, priming, or loading is required.
- Open the cover – Slide the cover down until you hear a click. This prepares one dose and decreases the dose counter by one. Only open the cover when you are ready to inhale immediately; opening and closing without inhaling wastes a dose.
- Breathe out fully – Hold the inhaler away from your mouth and breathe out completely and gently. Do not breathe out into the mouthpiece, as moisture can affect the powder.
- Seal your lips around the mouthpiece – Place the mouthpiece between your lips and close them firmly around it. Keep the inhaler level, and do not cover the small air vents on top of the device with your fingers.
- Inhale forcefully and deeply – Take one long, steady, deep breath in through your mouth (not your nose). Continue breathing in until your lungs feel full. A strong, consistent inspiratory flow is important for proper powder delivery.
- Hold your breath – Remove the inhaler from your mouth and hold your breath for 3–4 seconds, or as long as is comfortable. Then breathe out slowly and gently through your nose.
- Close the cover – Slide the cover upward to close the inhaler firmly. This protects the next dose.
- Rinse your mouth – Rinse your mouth with water and spit it out. This substantially reduces the risk of oral candidiasis and hoarseness. Do not swallow the rinse water.
Cleaning the device: The Ellipta inhaler does not need routine internal cleaning. If the mouthpiece needs wiping, use a dry tissue. Never wash the inhaler with water and never disassemble it. The device contains 30 doses; once the dose counter reaches zero, discard the inhaler (even if some powder remains visible).
If your breathing becomes wheezy or tight immediately after inhalation (paradoxical bronchospasm), do not take another dose. Use your rescue bronchodilator and contact your doctor promptly. A spacer device is not used with the Ellipta inhaler, as it is a breath-actuated dry powder device rather than a pressurised aerosol.
Missed Dose
If you forget to take a dose, take it as soon as you remember on the same day. If you do not remember until the next day, skip the missed dose and take your next dose at the usual time the following day. Do not take a double dose to make up for the missed inhalation. Taking more than one dose in 24 hours does not improve asthma or COPD control and increases the risk of side effects.
Overdose
Taking more than the prescribed dose (especially repeatedly or at high strength) may produce signs of excessive beta-agonist or corticosteroid activity, including rapid heartbeat (tachycardia), palpitations, tremor, headache, muscle cramps, low blood potassium (hypokalaemia), and elevated blood glucose. Prolonged overdose can lead to adrenal suppression and Cushingoid features.
If you accidentally take more puffs than directed on a single occasion, contact your doctor, pharmacist, or local poison control centre for advice. In the event of a deliberate or large overdose, emergency evaluation is warranted, with monitoring of heart rate, rhythm, blood pressure, potassium, and blood glucose. There is no specific antidote; treatment is supportive.
Even if you feel well, do not stop using Revinty Ellipta without speaking to your doctor. Abrupt discontinuation can lead to loss of asthma or COPD control, rebound symptoms, and exacerbations. If discontinuation is clinically appropriate, the dose should be reduced gradually under medical supervision.
What Are the Side Effects of Revinty Ellipta?
Revinty Ellipta is generally well tolerated. The most common side effects are headache, nasopharyngitis (common cold), upper respiratory tract infection, oral thrush, and hoarseness – together affecting more than 1 in 10 patients in some trials. Serious side effects, including pneumonia (in COPD) and severe allergic reactions, are uncommon to rare.
Like all medicines, Revinty Ellipta can cause side effects, although not everyone gets them. Most are mild and transient, and many relate to the local deposition of inhaled corticosteroid and beta-agonist in the mouth and throat. The overall safety profile of fluticasone furoate/vilanterol has been characterised in large randomised controlled trials involving more than 18,000 patients with asthma and COPD, including the landmark SUMMIT and Salford Lung Study programmes.
Severe allergic reaction (angioedema, anaphylaxis) with swelling of the face, lips, tongue, or throat; widespread rash or hives; sudden difficulty breathing or swallowing; or worsening wheezing immediately after inhalation (paradoxical bronchospasm). These reactions are rare but potentially life-threatening.
Very Common Side Effects
- Headache
- Nasopharyngitis (common cold, runny nose, sore throat)
Common Side Effects
- Upper respiratory tract infection
- Influenza-like illness
- Oral thrush (oropharyngeal candidiasis) – white patches in mouth or throat
- Pneumonia (more commonly in patients with COPD)
- Bronchitis
- Cough
- Oropharyngeal pain (sore throat)
- Sinusitis
- Back pain
- Joint pain (arthralgia)
- Muscle spasms
- Fever (pyrexia)
- Abdominal pain
Uncommon Side Effects
- Hoarseness or dysphonia (voice changes)
- Palpitations (awareness of the heartbeat)
- Tachycardia (fast heart rate)
- Tremor
- Anxiety
- Muscle cramps
- Viral respiratory tract infection
- Rash
- Extrasystoles (skipped or extra heartbeats)
Rare Side Effects
- Hypersensitivity reactions including angioedema, urticaria, and rash
- Anaphylactic reactions (rare but potentially life-threatening)
- Paradoxical bronchospasm – wheezing immediately after inhalation
- Severe cardiac arrhythmias, including atrial fibrillation and supraventricular tachycardia
Not Known (Frequency Cannot Be Estimated)
- Blurred vision and other visual disturbances (may indicate cataract or glaucoma, particularly with long-term use)
- Sleep disturbances and behavioural changes, including psychomotor hyperactivity, irritability, and, very rarely, depression (more commonly reported in children)
Systemic Corticosteroid Effects with Long-term Use
Like all inhaled corticosteroids, long-term or high-dose fluticasone furoate can produce systemic effects when absorbed into the circulation. These are dose-dependent and more likely with the higher 184/22 mcg strength used over months to years. Systemic effects can include:
- Adrenal suppression – reduced ability of the adrenal glands to produce cortisol naturally, particularly relevant during stress, surgery, or trauma
- Reduced growth velocity in adolescents – regular height monitoring is recommended for young patients on long-term ICS therapy
- Decreased bone mineral density and increased risk of osteoporosis, particularly in postmenopausal women, older men, or those with other risk factors
- Posterior subcapsular cataract and glaucoma – periodic eye examinations are recommended in long-term users
- Cushingoid features – moon face, central weight gain, thin skin, and bruising (uncommon at recommended doses)
- Increased susceptibility to infections – particularly respiratory infections, and in COPD patients, pneumonia
The risk of pneumonia is a specific consideration in COPD. Large trials and meta-analyses have shown that ICS-containing regimens, including fluticasone furoate/vilanterol, modestly increase the incidence of pneumonia in COPD patients compared with non-ICS therapy. Patients should be counselled to report promptly any symptoms of pneumonia such as fever, productive cough, increased sputum purulence, pleuritic chest pain, or worsening breathlessness.
If any side effects become troublesome, worrying, or persistent, inform your doctor or pharmacist. You can also report suspected side effects directly to your national pharmacovigilance authority (for example the MHRA Yellow Card Scheme in the UK or FDA MedWatch in the US). Reporting side effects helps to continuously monitor the benefit-risk balance of medicines.
How Should You Store Revinty Ellipta?
Store Revinty Ellipta below 25°C (77°F) in a dry place. Keep the inhaler in its sealed foil tray until ready for first use, and use within 6 weeks of opening the tray. Protect from heat, moisture, and freezing. Keep out of the sight and reach of children.
Proper storage is essential to ensure the powder formulation remains stable and delivers the correct dose throughout the in-use period. Follow these guidelines carefully:
- Store below 25°C (77°F) in a dry place. Do not refrigerate or freeze
- Keep the inhaler in its sealed foil tray to protect it from moisture until first use
- Once the foil tray has been opened, use the inhaler within 6 weeks. Write the “discard by” date on the label provided on the inhaler
- Keep the cover closed between doses to protect the mouthpiece and remaining powder
- Do not use the inhaler after the expiry date printed on the carton and foil tray. The expiry date refers to the last day of that month
- Keep this medicine out of the sight and reach of children
- Do not disassemble, wash, or immerse the inhaler in water
When the dose counter reaches zero, your inhaler is empty and should be discarded even if powder appears to remain inside. Return expired or empty inhalers to your pharmacy for safe disposal whenever possible. Do not dispose of medicines in household waste or flush them down the drain, as this helps to protect the environment.
What Does Revinty Ellipta Contain?
Each delivered dose contains fluticasone furoate 92 micrograms and vilanterol 22 micrograms (as vilanterol trifenatate). The inactive ingredients are lactose monohydrate (which contains small amounts of milk proteins) and magnesium stearate. The inhaler contains 30 pre-metered doses in two separate blister strips.
Revinty Ellipta is supplied as a white to off-white powder inside the Ellipta dry powder inhaler. Each inhaler contains two aluminium foil blister strips, each with 30 regularly spaced blisters. Upon activation, one blister from each strip opens simultaneously, and the powders combine in the mixing chamber as you inhale.
Active Ingredients (Per Delivered Dose)
- Fluticasone furoate 92 micrograms – a synthetic trifluorinated corticosteroid with high glucocorticoid receptor affinity and prolonged lung retention
- Vilanterol 22 micrograms (equivalent to 25 mcg of vilanterol trifenatate) – a selective long-acting beta-2 adrenergic agonist with approximately 24-hour duration of action
Inactive Ingredients
- Lactose monohydrate – carrier powder that facilitates dispersion of the active ingredients during inhalation. Contains trace amounts of cow’s milk protein
- Magnesium stearate (in the vilanterol strip only) – a lubricant that improves powder flow properties
The Ellipta inhaler is a plastic device with a grey body and a light blue cover. The mouthpiece is covered when not in use. A dose counter on the top of the device shows the number of doses remaining (numbers 30 down to 1, with the last 10 doses displayed in red as a warning).
Available Pack Sizes
- 30-dose inhaler – one month’s supply at the recommended dose of one inhalation daily
- Multipacks of 3 × 30-dose inhalers (90 doses) are available in some countries
Revinty Ellipta is manufactured by Glaxo Group Ltd, part of GSK (GlaxoSmithKline). Equivalent products marketed under the brand names Relvar Ellipta (Europe) and Breo Ellipta (United States, Canada) contain identical active ingredients in the same Ellipta device. Not all pack sizes or strengths may be marketed in every country.
Frequently Asked Questions About Revinty Ellipta
Revinty Ellipta (fluticasone furoate 92 mcg / vilanterol 22 mcg) is a once-daily combination inhaler used for the long-term maintenance treatment of asthma in adults and adolescents aged 12 years and older whose condition is not adequately controlled on an inhaled corticosteroid alone. The same strength is also indicated for symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD) who have an FEV1 below 70% predicted and a history of exacerbations. It is a preventer medicine, not a rescue inhaler.
Revinty Ellipta is distinctive because it provides true once-daily dosing for both the inhaled corticosteroid and the long-acting beta-agonist components – an unusual feature among ICS/LABA combinations, most of which are administered twice daily. The Ellipta device is a breath-actuated dry powder inhaler with 30 pre-loaded doses, and it requires no priming, shaking, or hand-breath coordination. Fluticasone furoate has a longer lung retention time than earlier inhaled corticosteroids, and vilanterol provides 24-hour bronchodilation, allowing sustained disease control with a single daily inhalation.
There is limited clinical data on fluticasone furoate/vilanterol use in pregnancy. International guidelines (GINA 2024) emphasise that poorly controlled asthma during pregnancy poses a greater risk to mother and fetus than the use of inhaled asthma medicines. Administration during pregnancy should only be considered if the expected benefit justifies the potential risk, and the lowest effective dose should be used. Always discuss your individual situation with your doctor, who may weigh the severity of your disease, your treatment response, and the available alternatives before making a recommendation.
Vilanterol produces rapid bronchodilation within 15 minutes of inhalation, with maximum effect reached in approximately one hour. However, the full anti-inflammatory benefit of fluticasone furoate develops gradually over 1 to 2 weeks of consistent daily use. Patients should continue taking Revinty Ellipta every day, even when feeling well, to maintain sustained asthma or COPD control. Doctors typically reassess lung function and symptoms after 4 to 12 weeks of regular use to confirm benefit and decide whether any treatment adjustment is needed.
No. Revinty Ellipta is a maintenance (preventer) medicine and must not be used to treat sudden asthma attacks or acute breathlessness. For acute symptoms, always use a short-acting bronchodilator rescue inhaler such as salbutamol or albuterol. If your rescue inhaler does not provide adequate or lasting relief, or if you need it more than twice a week for symptom relief, your asthma may not be well controlled and you should contact your doctor for review.
Oral thrush (oropharyngeal candidiasis) is a common side effect of Revinty Ellipta, as with other inhaled corticosteroids. It may affect up to 1 in 10 users. You can significantly reduce the risk by rinsing your mouth thoroughly with water (and spitting the water out) after every inhalation, and by brushing your teeth if possible. Rinsing does not reduce the anti-inflammatory effect of the medicine in the lungs. If white patches appear in your mouth or throat, a sore tongue, or a burning sensation, tell your doctor or pharmacist – thrush is typically treated with an antifungal mouth rinse or lozenges.
If you forget a dose, take it as soon as you remember on the same day. If you do not remember until the following day, skip the missed dose and take your next dose at the usual time. Do not take a double dose to make up for a missed one. Consistent daily use is important for maintaining asthma and COPD control, so consider linking your daily dose to another routine activity (such as brushing your teeth) or setting a daily phone reminder.
References
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2024 Update. Available at: ginasthma.org
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis and Management of COPD, 2024 Report. Available at: goldcopd.org
- European Medicines Agency (EMA). Revinty Ellipta (fluticasone furoate/vilanterol) – Summary of Product Characteristics (SmPC). Updated 2024.
- U.S. Food and Drug Administration (FDA). Breo Ellipta (fluticasone furoate and vilanterol) – Prescribing Information. Revised 2023.
- Woodcock A, Bleecker ER, Lotvall J, et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest. 2013;144(4):1222–1229.
- Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–1826. doi:10.1016/S0140-6736(16)30069-1
- Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1(3):210–223.
- Woodcock A, Vestbo J, Bakerly ND, et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial (Salford Lung Study). Lancet. 2017;390(10109):2247–2255.
- British National Formulary (BNF). Fluticasone furoate with vilanterol. National Institute for Health and Care Excellence (NICE). Accessed December 2025.
- Albertson TE, Bullick SW, Schivo M, Sutter ME. Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy. Drug Des Devel Ther. 2016;10:4047–4060.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List, 2023.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians with expertise in pulmonology, respiratory medicine, and clinical pharmacology.
All content is reviewed according to international guidelines including GINA 2024, GOLD 2024, EMA SmPC, FDA prescribing information, and British National Formulary (BNF). Evidence level: 1A.
Independent medical information with no commercial funding. No pharmaceutical company sponsorship. Content follows the GRADE evidence framework. Read our editorial standards.